References
1. Jain J, Sutton KS, Hong AL. Progress Update in Pediatric Renal
Tumors. Curr Oncol Rep . 2021;23(3):33.
doi:10.1007/s11912-021-01016-y
2. Daw NC, Chi Y-Y, Kim Y, et al. Treatment of stage I anaplastic Wilms’
tumour: a report from the Children’s Oncology Group AREN0321 study.Eur J Cancer . 2019;118:58-66. doi:10.1016/j.ejca.2019.05.033
3. Daw NC, Chi Y-Y, Kalapurakal JA, et al. Activity of Vincristine and
Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of
Stage II to IV Disease: Results of the Children’s Oncology Group
AREN0321 Study. J Clin Oncol . 2020;38(14):1558-1568.
doi:10.1200/jco.19.01265
4. Wagner L, Hill DA, Fuller C, et al. Treatment of Metastatic Rhabdoid
Tumor of the Kidney. J Pediatric Hematology Oncol .
2002;24(5):385-388. doi:10.1097/00043426-200206000-00012
5. Yamamoto M, Suzuki N, Hatakeyama N, et al. Treatment of Stage IV
Malignant Rhabdoid Tumor of the Kidney (MRTK) With ICE and VDCy. J
Pediatric Hematology Oncol . 2006;28(5):286-289.
doi:10.1097/01.mph.0000212901.84146.5a
6. Marina NM, Poquette CA, Cain AM, Jones D, Pratt CB, Meyer WH.
Comparative Renal Tubular Toxicity of Chemotherapy Regimens Including
Ifosfamide in Patients With Newly Diagnosed Sarcomas. J Pediatric
Hematology Oncol . 2000;22(2):112-118.
doi:10.1097/00043426-200003000-00007
7. Santos MLC, Brito BB de, Silva FAF da, Botelho AC dos S, Melo FF de.
Nephrotoxicity in cancer treatment: An overview. World J Clin
Oncol . 2020;11(4):190-204. doi:10.5306/wjco.v11.i4.190
8. Rossi R, Gödde A, Kleinebrand A, et al. Unilateral nephrectomy and
cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis
of 120 patients. J Clin Oncol . 1994;12(1):159-165.
doi:10.1200/jco.1994.12.1.159
9. Milano GM, Cozza R, Ilari I, De Sio L, Boldrini R, Jenkner A, De
Ioris M, Inserra A, Dominici C, Donfrancesco A. High histologic and
overall response to dose intensification of ifosfamide, carboplatin, and
etoposide with cyclophosphamide, doxorubicin, and vincristine in
patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù
Children’s Hospital experience. Cancer . 2006 Apr
15;106(8):1838-45. doi: 10.1002/cncr.21780. Erratum in: Cancer. 2006 Sep
15;107(6):1421. PMID: 16532434.
10. Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris
E, Laver JH, Reaman GH, Cairo MS. Ifosfamide, carboplatin and etoposide
in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer
Group report. Ann Oncol. 2002 Mar;13(3):460-9. doi:
10.1093/annonc/mdf028.
11. Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D’Angelo P,
Casazza G, Piva L, Luksch R, Perotti D, Pession A, Fagioli F, Dallorso
S. Treatment of high-risk relapsed Wilms tumor with dose-intensive
chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic
stem cell support: experience by the Italian Association of Pediatric
Hematology and Oncology. Pediatr Blood Cancer. 2008
Jul;51(1):23-8. doi: 10.1002/pbc.21524.
12. Ma C, Sridharan M, Al-Sayegh H, et al. Building a Harmonized
Datamart by Integrating Cross-Institutional Systems of Clinical,
Outcome, and Genomic Data: The Pediatric Patient Informatics Platform (
PPIP ). Jco Clin Cancer Informatics . 2021;5(5):202-215.
doi:10.1200/cci.20.00083
13. Venkatramani R, Shoureshi P, Malvar J, Zhou S, Mascarenhas L. High
dose alkylator therapy for extracranial malignant rhabdoid tumors in
children. Pediatr Blood Cancer . 2014;61(8):1357-1361.
doi:10.1002/pbc.25093
14. Sepe DM, Ginsberg JP, Balis FM. Dexrazoxane as a Cardioprotectant in
Children Receiving Anthracyclines. Oncol . 2010;15(11):1220-1226.
doi:10.1634/theoncologist.2010-0162
15. Jones DP, Chesney RW. Renal toxicity of cancer chemotherapeutic
agents in children. Curr Opin Pediatr . 1995;7(2):208-213.
doi:10.1097/00008480-199504000-00016
16. Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin
and etoposide in children with poor-risk relapsed Wilms’ tumor: a
Children’s Cancer Group report. Ann Oncol . 2002;13(3):460-469.
doi:10.1093/annonc/mdf028
17. Daw NC, Gregornik D, Rodman J, et al. Renal function after
ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy
and radiotherapy in children with wilms tumour. Eur J Cancer .
2009;45(1):99-106. doi:10.1016/j.ejca.2008.09.017
18. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of Ifosfamide and
Etoposide to Standard Chemotherapy for Ewing’s Sarcoma and Primitive
Neuroectodermal Tumor of Bone. New Engl J Medicine .
2003;348(8):694-701. doi:10.1056/nejmoa020890
19. Eaton BR, Claude L, Indelicato DJ, et al. Ewing sarcoma.Pediatr Blood Cancer . 2021;68(S2):e28355. doi:10.1002/pbc.28355
20. Womer RB, West DC, Krailo MD, et al. Randomized Controlled Trial of
Interval-Compressed Chemotherapy for the Treatment of Localized Ewing
Sarcoma: A Report From the Children’s Oncology Group. J Clin
Oncol . 2012;30(33):4148-4154. doi:10.1200/jco.2011.41.5703
TABLE 1. Patient characteristics